Ask AI
Selecting Patients for Bridging Therapy in RR MM

CE / CME

Identifying Patients Likely to Benefit From Bridging Therapy Before CAR T-Cell Infusion  in R/R MM 

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 29, 2025

Expiration: June 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which factor has been shown to be most associated with improved efficacy and reduced toxicity in patients receiving CAR T-cell therapy (eg, idecabtagene vicleucel [ide-cel] or ciltacabtagene autoleucel [cilta-cel]) for relapsed/refractory (R/R) multiple myeloma (MM)?